Rapport Therapeutics initiated Phase 3 trials (FOCUS 1 and FOCUS 2) for its drug RAP-219 targeting focal onset seizures, building on promising Phase 2a results showing significant seizure reduction. The company also advances trials for bipolar mania and is developing a long-acting injectable form of RAP-219, with topline bipolar mania data expected in October 2026. Financially, Rapport ended Q2 2026 with $436.1 million in cash, supporting operations into late 2029 despite a net loss of $56.6 million due to increased R&D and operational expenses. These developments position RAP-219 as a potential precision medicine breakthrough in neurological disorders, with further expansion planned into primary generalized tonic-clonic seizures and chronic pain treatments.
Bitcoin's price surged past $84,000 on September 21, closing above its 50-week moving average for the first time in 45 weeks, a key technical milestone that suggests the bear market may be over. Analysts like Alex Thorn and Ted Pillows highlight that...
TRX is trading in a critical pullback zone between $0.3389 and $0.3393, with upside targets at $0.3469, $0.3535, and $0.3611. Derivatives volume and open interest have risen, indicating increased trader activity. Tron Inc. has added 147,132 TRX to it...
VanEck's Bitcoin ChainCheck report highlights Metaplanet's executive option pool at 14.7% of fully diluted shares, far above peers, raising dilution concerns for shareholders. Officer exposure is 8.2%, nearly ten times the average among major Bitcoin...
Cardano's delegated representatives voted down a $12.29 million funding request for Input Output's Pogun project, designed to integrate Bitcoin into decentralized finance. Although the Constitutional Committee unanimously approved the proposal, the D...
Broadcom has declared its next quarterly dividend of $0.65 per share, payable on September 30, 2026, unchanged from the previous quarter. This marks the company's 16th consecutive year of dividend increases, highlighting its commitment to long-term d...
